Cardiologist - Heart Failure, Heart Transplant, Cardiac Amyloidosis, Cardio-Oncology, ICU and Cardiac Arrest
Duesseldorf
Joined January 2015
- Tweets50
- Following219
- Followers68
- Likes134
Fabian Voß retweeted
JUST PUBLISHED @JACCJournals bit.ly/EuroTRScore See Online score EuroTR.eu Congrats @j_hausleiter @JennifervStein @KP_Kresoja @PhilippLurz @MariannaAdamo1 @Sticchi_Alex @JGrapsa @MarcoMetra @escardio @ACCinTouch
Fabian Voß retweeted
New🔥 #CSWG study: 🔑 messages:
1) most changes in clinical trajectories in CS patients occur within the first 6h of admission already (#goldenshift) ⏱️
2) phenotyping and SCAI staging can be combined to improve risk stratification!🎯
sciencedirect.com/science/ar…
Fabian Voß retweeted
🔥 🔥 2 state of art 🗞️ on
📍 Non-amyloid specific
📍 Amyloid specific
Treatments of #ATTR
🔍What you can do with the 4 pillars & more
🔬 From stabilizers to siRNA & gene editing 🧬
@HFUAcademy 🫀
👉bit.ly/4h3GFKq
👉bit.ly/4q7YThQ
@ESC_Journals
@ehj_ed @EJHFEiC
@dr_pavia @MicheleEmdin @AlbertoAimo90 @IacopoOlivotto @glimongelli @DrMarthaGulati @stefanocarugo @ShelleyZieroth @scottdsolomon @DrRajivsankar @KTamirisaMD @mvaduganathan
Fabian Voß retweeted
🚨Recently Published in #CardioOncology
Evaluation of a screening algorithm to detect cardiac amyloidosis in mild to severe aortic valve stenosis🫀
#OpenAccess
Read more➡️doi.org/p7c4 @vofab @ICOSociety
Fabian Voß retweeted
#Wire-Based Interventional Clip Excision (WICE Procedure) to Allow Tran... sciencedirect.com/science/ar…
🔍 New #treatment approach for recurrent tricuspid regurgitation after #TEER!
#TricuspidValve #TTVR #StructuralHeart #InterventionalCardiology #CardiologyResearch #AgPolzin
Fabian Voß retweeted
In this multicenter European registry, those patients in mid stage but not those in early or late stage of Tricuspid Regurgitation disease, showed significant 1-year survival with #TTEER vs conservative management. 4-parameter easy score to identify them. Thanks to the authors.
Fabian Voß retweeted
I’m honored to soon be serving on the steering committee of the CSWG alongside my fellow #cardiogenic #shock warriors, following the vision and leadership of @NavinKapur4 @BurkhoffMd @manreetkanwar @JHMontfort10 @ShashankSinhaMD and @ReshadGaranMD
Congratulations to the CSWG Exec Steering Committee for a fantastic decade of passion partnership and perseverance advancing care for the sickest patients. As we enter decade #2 please welcome our new #CSWG Steering Committee #Leaders @JHMontfort10
Fabian Voß retweeted
Presented at #AHA24:
In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo. Full trial results: nej.md/48OTgx4
ALT A graph showing the mean percent change in the transthyretin (TTR) level after a single intravenous infusion of nexiguran ziclumeran (nex-z) through 24 months.
Fabian Voß retweeted
🫀#RealWorldData on cardiac #amyloidosis treatment!
64% of #ATTRCM patients meet tafamidis trial criteria with treated patients showing higher #survival rates. High need for early detection🔥
Online: bit.ly/ESCHF_attrrwd
@PiotrPonikowski #ATTR #HeartFailure #CardioTwitter
Fabian Voß retweeted
Original Article: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation (TRISCEND II) nej.md/4dTODm5
Editorial: Early-Stage Results with Transcatheter Tricuspid-Valve Replacement nej.md/4e29F2f
#TCT2024 | @crfheart
ALT A diagram of the primary safety and effectiveness at 1 year.
ALT Kaplan–Meier estimates for prespecified events adjudicated by the clinical events committee (CEC) at 1 year.
ALT Charts showing clinical, functional, quality-of-life, and tricuspid-regurgitation changes at 1 year.
Fabian Voß retweeted
Congratulations to @ElricZweck, #JacobMoller and team for their late breaking work on #AKI in #AMICS at #TCT2024 with a simultaneous publication in @CircAHA - ahajournals.org/doi/10.1161/…. I had the privilege of writing the editorial comment ahajournals.org/doi/10.1161/…. @BrownUnivHealth
Fabian Voß retweeted
🚨 MAJOR news in the #ATTR #amyloidosis world! Today the much-anticipated HELIOS-B results were presented @escardio & simultaneously published in @NEJM. The largest ATTR-CM trial published to date, testing #vutrisiran vs. placebo. Bottom line: Huge win for vutrisiran! Lowered CV events and All-Cause mortality in the overall population & as monotherapy. Now, let’s take a deep dive into the results… nejm.org/doi/full/10.1056/NE…
Fabian Voß retweeted
A herculean #cardioonc effort amongst experts in assembling this statement on the rapidly evolving landscape of CV toxicities in cancer immunotherapeutics.
Great resource to study more of what we don't know!
👏to colleagues and friends
@ESC_Journals
doi.org/10.1002/ejhf.3340
Thanks for sharing our latest publication @SN_Oncology and even more to the whole Team and all participating patients!
@florian_bonner @RalfWestenfeld @cjungMD @DanielScheiber @SM_Haberkorn @amin_polzin
Anthracycline therapy induces an early decline of systolic mayocardial function even among young breast cancer patients without known cardiovascular risk factor @vofab @florian_bonner @RalfWestenfeld @DanielScheiber @cjungMD @amin_polzin @UniklinikDUS rdcu.be/dOGKo
Fabian Voß retweeted
1/2 Following the DANGER SHOCK trial demonstrating reduced mortality with Impella in cardiogenic shock, the independent DSMB of the RECOVER IV trial has strongly recommended the trial be discontinued because of lack of equipoise. Therefore, we are ceasing enrollment in the trial.
Fabian Voß retweeted
We are proud to announce that the cardiology team at @UniklinikDUS successfully performed the first interventional transfemoral tricuspid valve replacement this week! A huge thank you to the entire team!
Fabian Voß retweeted
💥Happy to share publication of pilot phase of our German Cardiac Arrest Registry (G-CAR):
link.springer.com/content/pd…
➡️ next step: assessment of PROs
🙏 Thanks to all the investigators!
#CardiacArrest #OHCA
@DGK_AG3 @AnneFreund3 @thiele_holger @jochen_dutzmann @EPTIG
Fabian Voß retweeted
🔴 SGLT2 Inhibitor Therapy in Patients With TTR Amyloid Cardiomyopathy @JACCJournals #CardioEd #Cardiology #FOAMed #Amyloidosis
Happy to share our latest article discussing mitochondrias oxidative capacity in different subtypes of cardiac amyloidosis published by @JACCJournals !
@DanielScheiber @ElricZweck @RalfWestenfeld @amin_polzin
New 🔥 article from our Düsseldorf lab, just published in @JACCJournals Heart Failure:
Cardiac light-chain vs. transthyretin #amyloidosis have distinct mitochondrial characteristics @vofab @DanielScheiber @RalfWestenfeld @amin_polzin @DGK_org @BiykemB
jacc.org/doi/10.1016/j.jchf.…
Fabian Voß retweeted
@ElricZweck presents master class on ML used in #CSWG work! 👏👏👏@manreetkanwar @NavinKapur4 @JHMontfort10 @lisong2003
